Anti-cd74 antibody conjugates, compositions comprising anti cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
AssigneeSutro Biopharma, Inc.
InventorsRyan STAFFORD, Alice YAM, Avinash GILL, Kalyani PENTA, Xiaofan LI, Aaron SATO
Life of this patent
Estimating the term…
Abstract
Provided herein are antibody conjugates with binding specificity for CD74 and compositions comprising the antibody conjugates, including pharmaceutical compositions, methods of producing the conjugates, and methods of using the conjugates and compositions for therapy.
Claims26
An antibody conjugate comprising an antibody that specifically binds to CD74 linked site-specifically to at least one payload moiety, wherein the antibody comprises a non-natural amino acid at a site selected from the group consisting of HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70, according to the Kabat, Chothia, or EU numbering scheme, and wherein the antibody comprises three heavy chain CDRs and three light chain CDRs of a VH-VL pair selected from the group consisting of:
- a. the VH region SEQ ID NO:
- 236 and the VL region SEQ ID NO:
- 256;
- b. the VH region SEQ ID NO:
- 236 and the VL region SEQ ID NO:
- 257;
- c. the VH region SEQ ID NO:
- 236 and the VL region SEQ ID NO:
- 265;
- d. the VH region SEQ ID NO:
- 236 and the VL region SEQ ID NO:
- 264;
- e. the VH region SEQ ID NO:
- 236 and the VL region SEQ ID NO:
- 267;
- f. the VH region SEQ ID NO:
- 236 and the VL region SEQ ID NO:
- 268;
- g. the VH region SEQ ID NO:
- 236 and the VL region SEQ ID NO:
- 269;
- h. the VH region SEQ ID NO:
- 236 and the VL region SEQ ID NO:
- 270;
- i. the VH region SEQ ID NO:
- 237 and the VL region SEQ ID NO:
- 256;
- j. the VH region SEQ ID NO:
- 237 and the VL region SEQ ID NO:
- 257;
- k. the VH region SEQ ID NO:
- 237 and the VL region SEQ ID NO:
- 265;
- l. the VH region SEQ ID NO:
- 237 and the VL region SEQ ID NO:
- 264;
- m. the VH region SEQ ID NO:
- 237 and the VL region SEQ ID NO:
- 267;
- n. the VH region SEQ ID NO:
- 237 and the VL region SEQ ID NO:
- 268;
- o. the VH region SEQ ID NO:
- 237 and the VL region SEQ ID NO:
- 269;
- p. the VH region SEQ ID NO:
- 237 and the VL region SEQ ID NO:
- 270;
- q. the VH region SEQ ID NO:
- 238 and the VL region SEQ ID NO:
- 256;
- r. the VH region SEQ ID NO:
- 238 and the VL region SEQ ID NO:
- 257;
- s. the VH region SEQ ID NO:
- 238 and the VL region SEQ ID NO:
- 265;
- t. the VH region SEQ ID NO:
- 238 and the VL region SEQ ID NO:
- 264;
- u. the VH region SEQ ID NO:
- 238 and the VL region SEQ ID NO:
- 267;
- v. the VH region SEQ ID NO:
- 238 and the VL region SEQ ID NO:
- 268;
- w. the VH region SEQ ID NO:
- 238 and the VL region SEQ ID NO:
- 269;
- x. the VH region SEQ ID NO:
- 238 and the VL region SEQ ID NO:
- 270;
- v. the VH region SEQ ID NO:
- 239 and the VL region SEQ ID NO:
- 256;
- z. the VH region SEQ ID NO:
- 239 and the VL region SEQ ID NO:
- 257;
- aa. the VH region SEQ ID NO:
- 239 and the VL region SEQ ID NO:
- 265;
- bb. the VH region SEQ ID NO:
- 239 and the VL region SEQ ID NO:
- 264;
- cc. the VH region SEQ ID NO:
- 239 and the VL region SEQ ID NO:
- 267;
- dd. the VH region SEQ ID NO:
- 239 and the VL region SEQ ID NO:
- 268;
- ee. the VH region SEQ ID NO:
- 239 and the VL region SEQ ID NO:
- 269;
- ff. the VH region SEQ ID NO:
- 239 and the VL region SEQ ID NO:
- 270;
- gg. the VH region SEQ ID NO:
- 235 and the VL region SEQ ID NO:
- 256;
- hh. the VH region SEQ ID NO:
- 240 and the VL region SEQ ID NO:
- 256;
- and
- ii. the VH region SEQ ID NO:
- 241 and the VL region SEQ ID NO:
- 256.
(canceled)
-33. (canceled)
-36. (canceled)
-44. (canceled)
Dependencies are inferred from the claim text.